Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 2
2008 2
2009 5
2010 1
2011 3
2012 3
2013 2
2014 4
2015 3
2016 2
2017 2
2018 1
2019 2
2020 2
2021 6
2022 1
2023 1
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H, Fukagawa M, Hirakata H, Kagimura T, Fukushima M, Akizawa T; LANDMARK Investigators and Committees. Ogata H, et al. JAMA. 2021 May 18;325(19):1946-1954. doi: 10.1001/jama.2021.4807. JAMA. 2021. PMID: 34003226 Free PMC article. Clinical Trial.
IMPORTANCE: Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more effective than calcium-based binders for reducing cardiovascular events. OBJECTIVE: To determine whether lanthanum carbonate reduces …
IMPORTANCE: Among patients with hyperphosphatemia undergoing dialysis, it is unclear whether non-calcium-based phosphate binders are more ef …
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.
Neuen BL, Perkovic V, Agarwal R, Cherney DZI, Lam CSP, Wanner C, Tuttle KR, Sarafidis P, Barratt J, Burgner A, Chen X, Chew-Wong A, Dobronravov VA, Floege J, McCafferty K, Nangaku M, Packham D, Papachristou E, Pergola PE, Speeckaert MM, Subbiah A, Tang SCW, Tang S, Yeo SC, Jongs N, Smeijer JD, Berger M, Brinker M, Dayoub R, Elliott J, Li N, Mueller K, Rethemeier N, Finkelsztein MY, Heerspink HJL; FIND-CKD Investigators. Neuen BL, et al. JAMA. 2026 Jun 5:e269923. doi: 10.1001/jama.2026.9923. Online ahead of print. JAMA. 2026. PMID: 42246414 Free article.
Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T, Nohara S, Morikawa N, Shibao K, Ito S, Shibata R, Toh U, Nagafuji K, Fukami K, Fukumoto Y. Shibata T, et al. Among authors: fukami k. Eur J Prev Cardiol. 2023 Dec 21;30(18):1941-1949. doi: 10.1093/eurjpc/zwad210. Eur J Prev Cardiol. 2023. PMID: 37352112 Free article.
AIMS: Cancer treatment-related cardiovascular toxicity (CTR-CVT) is a growing concern in patients undergoing anticancer therapy. ...Key findings include This prospective study conducted in Japan revealed a high incidence of adverse cardiovascular (CV) events in pati …
AIMS: Cancer treatment-related cardiovascular toxicity (CTR-CVT) is a growing concern in patients undergoing anticancer therapy. ...K …
Carnitine Deficiency in Chronic Kidney Disease: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.
Kaida Y, Taguchi K, Fukami K. Kaida Y, et al. Among authors: fukami k. Nutrients. 2025 Jun 23;17(13):2084. doi: 10.3390/nu17132084. Nutrients. 2025. PMID: 40647189 Free PMC article. Review.
Carnitine deficiency is linked to a wide range of clinical manifestations, including muscle weakness, treatment-resistant anemia, intradialytic hypotension, mental disorder, and cardiovascular disease. This review provides a comprehensive overview of the physiological func …
Carnitine deficiency is linked to a wide range of clinical manifestations, including muscle weakness, treatment-resistant anemia, intradialy …
Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome.
Taguchi K, Elias BC, Brooks CR, Ueda S, Fukami K. Taguchi K, et al. Among authors: fukami k. Circ J. 2019 Dec 25;84(1):2-8. doi: 10.1253/circj.CJ-19-0872. Epub 2019 Dec 11. Circ J. 2019. PMID: 31827008 Free article. Review.
CKD patients are at high risk of developing cardiovascular disease (CVD), including coronary artery disease, heart failure and stroke. ...
CKD patients are at high risk of developing cardiovascular disease (CVD), including coronary artery disease, heart failure and stroke …
Role of AGEs in diabetic nephropathy.
Fukami K, Yamagishi S, Ueda S, Okuda S. Fukami K, et al. Curr Pharm Des. 2008;14(10):946-52. doi: 10.2174/138161208784139710. Curr Pharm Des. 2008. PMID: 18473844 Review.
Further, recently, the cross-talk between AGEs and the renin-angiotensin system (RAS) has been proposed to participate in diabetic nephropathy. In addition, activation of the RAS elicits ROS generation and subsequently stimulates growth factor and cytokine production by ki …
Further, recently, the cross-talk between AGEs and the renin-angiotensin system (RAS) has been proposed to participate in diabetic ne …
Role of AGEs-RAGE system in cardiovascular disease.
Fukami K, Yamagishi S, Okuda S. Fukami K, et al. Curr Pharm Des. 2014;20(14):2395-402. doi: 10.2174/13816128113199990475. Curr Pharm Des. 2014. PMID: 23844818 Review.
Thus, blockade of the AGEs/HMGB-1-RAGE system may be a promising therapeutic target for preventing diabetes- and/or age-related CVD. We review here the pathological role of the AGEs/HMGB-1-RAGE system in various types of CVD....
Thus, blockade of the AGEs/HMGB-1-RAGE system may be a promising therapeutic target for preventing diabetes- and/or age-related CVD. …
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S, Yamagishi SI, Matsumoto Y, Fukami K, Okuda S. Ueda S, et al. Among authors: fukami k. Clin Exp Nephrol. 2007 Jun;11(2):115-121. doi: 10.1007/s10157-007-0471-x. Epub 2007 Jun 28. Clin Exp Nephrol. 2007. PMID: 17593510 Review.
Endothelial dysfunction due to the reduced bioavailability of nitric oxide (NO) is involved in the course of atherosclerotic cardiovascular disease as well as chronic kidney disease (CKD). NO is synthesized from L-arginine via the action of NO synthase, which is blocked by …
Endothelial dysfunction due to the reduced bioavailability of nitric oxide (NO) is involved in the course of atherosclerotic cardiovascul …
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
Agarwal R, Correa-Rotter R, Navaneethan SD, Fukami K, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Nangaku M, Rosenstock J, Rossing P, Vaduganathan M, Scott C, Li L, Aldworth C, Green JB, Weir MR. Agarwal R, et al. Among authors: fukami k. J Am Soc Nephrol. 2026 Mar 29. doi: 10.1681/ASN.0000001071. Online ahead of print. J Am Soc Nephrol. 2026. PMID: 41905767
BACKGROUND: eGFR decline is common with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system inhibitors, often prompting treatment interruption or cessation, limiting cardiorenal benefits. ...METHODS: Evaluable participants ( N =790) with type 2 diabetes, …
BACKGROUND: eGFR decline is common with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system inhibitors, often prom …
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Taguchi K, Fukami K, Elias BC, Brooks CR. Taguchi K, et al. Among authors: fukami k. Toxins (Basel). 2021 May 19;13(5):361. doi: 10.3390/toxins13050361. Toxins (Basel). 2021. PMID: 34069405 Free PMC article. Review.
CKD is associated with poor outcomes due to high frequencies of comorbidities such as heart failure and cardiovascular disease. Uremic toxins are compounds that are usually filtered and excreted by the kidneys. ...Trimethylamine N-oxide (TMAO) generated by gut microbiota i …
CKD is associated with poor outcomes due to high frequencies of comorbidities such as heart failure and cardiovascular disease. Uremi …
43 results